Friday, November 06, 2015 12:39:42 PM
To this end, the Board of Directors has given management the mandate to accelerate our partnering initiatives in order to acquire the resources necessary to move the rest of the portfolio forward. Given the diversity and robustness of our rich clinical pipeline, many options exist to best execute on this directive while preserving and/or transferring value to our shareholders along the way. The Company had previously made the decision to transact on the diagnostics portfolio in order to become a pure-play therapeutics company. We will likely take this approach one step further and also seek to transact on either ESS or Eltoprazine in order to further refine the Company’s profile into a regenerative medicine company (ESS + MANF + Phenoguard) or a neurology company (Eltoprazine + MANF + Phenoguard), and achieve economic benefit from such a transaction. In looking at the pipeline, it is critical to note the late stage nature of ESS and Eltoprazine; each of these assets, individually, could provide a pipeline for a very valuable standalone public company.
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM